论文部分内容阅读
目的观察评价纳洛酮治疗慢性阻塞性肺疾病(COPD)所致肺性脑病临床疗效及安全性。方法将入选70例病例随机分为治疗组及对照组,两组均予以积极控制感染,持续低流量吸氧(给氧浓度为30%~40%,氧流量为1~3L/min,鼻导管给氧法),解痉平喘,保持气道通畅,维持酸碱、水、电解质平衡,营养支持等综合治疗。治疗组在此基础上加用纳洛酮注射剂(0.4mg/支),首剂负荷量0.8mg加入生理盐水20ml中静脉推注,以后给予纳洛酮注射剂4mg加入生理盐水500ml中,用微量泵24h持续静脉泵入,连用7d。结果治疗后,治疗组总有效率显著高于对照组(P<0.05);治疗过程中无不良反应发生。结论纳洛酮治疗COPD所致肺性脑病临床疗效确切、安全。
Objective To evaluate the clinical efficacy and safety of naloxone in the treatment of pulmonary encephalopathy caused by chronic obstructive pulmonary disease (COPD). Methods 70 cases were randomly divided into treatment group and control group. Both groups were given active infection control, continuous low-flow oxygen inhalation (oxygen concentration of 30% -40%, oxygen flow rate of 1-3L / min, nasal cannula Oxygen method), antispasmodic asthma, maintain airway patency, maintain acid-base, water, electrolyte balance, nutritional support and other comprehensive treatment. On the basis of this, the treatment group was given naloxone injection (0.4mg / support) and the first dose of 0.8mg was added to 20ml of normal saline for intravenous injection. After that, 4mg of naloxone injection was added to 500ml of normal saline, 24h continuous intravenous pump, once every 7d. Results After treatment, the total effective rate in the treatment group was significantly higher than that in the control group (P <0.05). No adverse reactions occurred during the treatment. Conclusion Naloxone is effective and safe in the treatment of pulmonary encephalopathy caused by COPD.